The therapeutic efficacy, adverse reactions and usefulness of ceftizoxime (FK 749, CZX) were objectively compared with those of cefazolin (CEZ) in 228 patients with pneumonia or chronic respiratory tract infection in a double-blind comparative study at 31 institutions in Japan. Patients were given daily 4 g of ceftizoxime or cefazolin in 2 divided doses by i. v. drip infusion for, in principle, 14 days. The results were as follows: 1) No significant difference was observed between the therapeutic efficacy of ceftizoxime 4g/day and that of cefazolin 4 g/day. 2) The improvement in chest rale in patients with pneumonia or lung abscess was significantly better in the ceftizoxime group than in the cefazolin group on the 3 rd day of dosing. The improvement in CRP was significantly better in the cefazolin group than in the ceftizoxime group on the 14 th day of dosing. The improvement in erythrocyte sedimentation rate of patients with respiratory tract infection except pneumonia and lung abscess was significantly better in the ceftizoxime group than in the cefazolin group on the 3 rd day. 3) No significant difference was observed between the two drug groups in bacteriological efficacy against causative organisms isolated from patients. 4) Significant differences were noted between the two drug groups in incidence of side effects; fever occurred in many patients of the ceftizoxime group (Fever was attributed to contamination by trace amounts of impurities). 5) No significant difference in usefulness was observed between the two drug groups. These findings suggest that the therapeutic efficacy of ceftizoxime 4 g/day was almost the same as that of cefazolin 4 g/day, but it was impossible to compare accurately the efficacy and safety of ceftizoxime with those of cefazolin because fever not attributable to ceftizoxime occured very frequently.
ASJC Scopus subject areas